Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.

Takano K, Saeki C, Oikawa T, Hidaka A, Mizuno Y, Ishida J, Takakura K, Nakano M, Torisu Y, Amano K, Ishikawa T, Zeniya M, Tsubota A, Saruta M.

J Gastroenterol Hepatol. 2019 Nov 1. doi: 10.1111/jgh.14900. [Epub ahead of print]

PMID:
31677185
2.

Encephalopathy Induced by High Plasma and Cerebrospinal Fluid Ceftriaxone Concentrations in a Hemodialysis Patient.

Suzuki S, Naito S, Numasawa Y, Asada M, Shoji N, Zeniya M, Takahashi D, Sato H, Iimori S, Nomura N, Sohara E, Okado T, Ishiwata Y, Nagata M, Rai T, Yokota T, Uchida S.

Intern Med. 2019 Jun 15;58(12):1775-1779. doi: 10.2169/internalmedicine.1785-18. Epub 2019 Feb 25.

3.

CD4+ T cells from patients with primary biliary cholangitis show T cell activation and differentially expressed T-cell receptor repertoires.

Nakagawa R, Muroyama R, Saeki C, Oikawa T, Kaise Y, Koike K, Arai J, Nakano M, Matsubara Y, Takano K, Hirata Y, Saruta M, Zeniya M, Kato N.

Hepatol Res. 2019 Jun;49(6):653-662. doi: 10.1111/hepr.13318. Epub 2019 Feb 26.

PMID:
30690835
4.

POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33.

Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, Aiba Y, Nakamura H, Kouno H, Kouno H, Ohta H, Sugi K, Nikami T, Yamashita T, Katsushima S, Komeda T, Ario K, Naganuma A, Shimada M, Hirashima N, Yoshizawa K, Makita F, Furuta K, Kikuchi M, Naeshiro N, Takahashi H, Mano Y, Yamashita H, Matsushita K, Tsunematsu S, Yabuuchi I, Nishimura H, Shimada Y, Yamauchi K, Komatsu T, Sugimoto R, Sakai H, Mita E, Koda M, Nakamura Y, Kamitsukasa H, Sato T, Nakamuta M, Masaki N, Takikawa H, Tanaka A, Ohira H, Zeniya M, Abe M, Kaneko S, Honda M, Arai K, Arinaga-Hino T, Hashimoto E, Taniai M, Umemura T, Joshita S, Nakao K, Ichikawa T, Shibata H, Takaki A, Yamagiwa S, Seike M, Sakisaka S, Takeyama Y, Harada M, Senju M, Yokosuka O, Kanda T, Ueno Y, Ebinuma H, Himoto T, Murata K, Shimoda S, Nagaoka S, Abiru S, Komori A, Migita K, Ito M, Yatsuhashi H, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, Tokunaga K, Nakamura M.

Sci Rep. 2019 Jan 14;9(1):102. doi: 10.1038/s41598-018-36490-1.

5.

Non-alcoholic fatty liver disease in patients with autoimmune hepatitis.

Takahashi A, Arinaga-Hino T, Ohira H, Abe K, Torimura T, Zeniya M, Abe M, Yoshizawa K, Takaki A, Suzuki Y, Kang JH, Nakamoto N, Fujisawa T, Tanaka A, Takikawa H; Japan AIH Study Group (JAIHSG).

JGH Open. 2018 Mar 30;2(2):54-58. doi: 10.1002/jgh3.12046. eCollection 2018 Apr.

6.

Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey.

Takahashi A, Moriya K, Ohira H, Arinaga-Hino T, Zeniya M, Torimura T, Abe M, Takaki A, Kang JH, Inui A, Fujisawa T, Yoshizawa K, Suzuki Y, Nakamoto N, Koike K, Yoshiji H, Goto A, Tanaka A, Younossi ZM, Takikawa H; Japan AIH Study Group.

PLoS One. 2018 Oct 4;13(10):e0204772. doi: 10.1371/journal.pone.0204772. eCollection 2018.

7.

Dialysis Case Volume Associated With In-Hospital Mortality in Maintenance Dialysis Patients.

Mandai S, Sato H, Iimori S, Naito S, Mori T, Takahashi D, Zeniya M, Nomura N, Sohara E, Okado T, Uchida S, Fushimi K, Rai T.

Kidney Int Rep. 2017 Nov 3;3(2):356-363. doi: 10.1016/j.ekir.2017.10.015. eCollection 2018 Mar.

8.

Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey.

Joshita S, Yoshizawa K, Umemura T, Ohira H, Takahashi A, Harada K, Hiep NC, Tsuneyama K, Kage M, Nakano M, Kang JH, Koike K, Zeniya M, Yasunaka T, Takaki A, Torimura T, Abe M, Yokosuka O, Tanaka A, Takikawa H; Japan Autoimmune Hepatitis Study Group (JAIHSG).

J Gastroenterol. 2018 Sep;53(9):1079-1088. doi: 10.1007/s00535-018-1444-4. Epub 2018 Feb 23.

PMID:
29476251
9.

Loop diuretics are associated with greater risk of sarcopenia in patients with non-dialysis-dependent chronic kidney disease.

Ishikawa S, Naito S, Iimori S, Takahashi D, Zeniya M, Sato H, Nomura N, Sohara E, Okado T, Uchida S, Rai T.

PLoS One. 2018 Feb 15;13(2):e0192990. doi: 10.1371/journal.pone.0192990. eCollection 2018.

10.

Role of ClC-K and barttin in low potassium-induced sodium chloride cotransporter activation and hypertension in mouse kidney.

Nomura N, Shoda W, Wang Y, Mandai S, Furusho T, Takahashi D, Zeniya M, Sohara E, Rai T, Uchida S.

Biosci Rep. 2018 Jan 30;38(1). pii: BSR20171243. doi: 10.1042/BSR20171243. Print 2018 Feb 28.

11.

The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1.

Zeniya M, Mori T, Yui N, Nomura N, Mandai S, Isobe K, Chiga M, Sohara E, Rai T, Uchida S.

Sci Rep. 2017 Oct 12;7(1):13086. doi: 10.1038/s41598-017-13486-x.

12.

Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation Spectroscopy.

Yoshizaki Y, Mori T, Ishigami-Yuasa M, Kikuchi E, Takahashi D, Zeniya M, Nomura N, Mori Y, Araki Y, Ando F, Mandai S, Kasagi Y, Arai Y, Sasaki E, Yoshida S, Kagechika H, Rai T, Uchida S, Sohara E.

Sci Rep. 2017 Jun 21;7(1):3945. doi: 10.1038/s41598-017-04233-3.

13.

Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients.

Nguyen Canh H, Harada K, Ouchi H, Sato Y, Tsuneyama K, Kage M, Nakano M, Yoshizawa K, Takahashi A, Abe M, Kang JH, Koike K, Inui A, Fujisawa T, Takaki A, Arinaga-Hino T, Torimura T, Suzuki Y, Fujiwara K, Zeniya M, Ohira H, Tanaka A, Takikawa H; Intractable Liver and Biliary Diseases Study Group of Japan.

J Clin Pathol. 2017 Nov;70(11):961-969. doi: 10.1136/jclinpath-2016-204271. Epub 2017 Apr 20.

PMID:
28428284
14.

Impaired degradation of medullary WNK4 in the kidneys of KLHL2 knockout mice.

Kasagi Y, Takahashi D, Aida T, Nishida H, Nomura N, Zeniya M, Mori T, Sasaki E, Ando F, Rai T, Uchida S, Sohara E.

Biochem Biophys Res Commun. 2017 May 27;487(2):368-374. doi: 10.1016/j.bbrc.2017.04.068. Epub 2017 Apr 14.

PMID:
28414128
15.

WNK4 is an Adipogenic Factor and Its Deletion Reduces Diet-Induced Obesity in Mice.

Takahashi D, Mori T, Sohara E, Tanaka M, Chiga M, Inoue Y, Nomura N, Zeniya M, Ochi H, Takeda S, Suganami T, Rai T, Uchida S.

EBioMedicine. 2017 Apr;18:118-127. doi: 10.1016/j.ebiom.2017.03.011. Epub 2017 Mar 8.

16.

miR-425 regulates inflammatory cytokine production in CD4+ T cells via N-Ras upregulation in primary biliary cholangitis.

Nakagawa R, Muroyama R, Saeki C, Goto K, Kaise Y, Koike K, Nakano M, Matsubara Y, Takano K, Ito S, Saruta M, Kato N, Zeniya M.

J Hepatol. 2017 Jun;66(6):1223-1230. doi: 10.1016/j.jhep.2017.02.002. Epub 2017 Feb 10.

PMID:
28192189
17.

Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis.

Torisu Y, Nakano M, Takano K, Nakagawa R, Saeki C, Hokari A, Ishikawa T, Saruta M, Zeniya M.

World J Hepatol. 2017 Jan 8;9(1):57-63. doi: 10.4254/wjh.v9.i1.57.

18.

Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population.

Kawashima M, Hitomi Y, Aiba Y, Nishida N, Kojima K, Kawai Y, Nakamura H, Tanaka A, Zeniya M, Hashimoto E, Ohira H, Yamamoto K, Abe M, Nakao K, Yamagiwa S, Kaneko S, Honda M, Umemura T, Ichida T, Seike M, Sakisaka S, Harada M, Yokosuka O, Ueno Y, Senju M, Kanda T, Shibata H, Himoto T, Murata K, Miyake Y, Ebinuma H, Taniai M, Joshita S, Nikami T, Ota H, Kouno H, Kouno H, Nakamuta M, Fukushima N, Kohjima M, Komatsu T, Komeda T, Ohara Y, Muro T, Yamashita T, Yoshizawa K, Nakamura Y, Shimada M, Hirashima N, Sugi K, Ario K, Takesaki E, Naganuma A, Mano H, Yamashita H, Matsushita K, Yamauchi K, Makita F, Nishimura H, Furuta K, Takahashi N, Kikuchi M, Masaki N, Tanaka T, Tamura S, Mori A, Yagi S, Shirabe K, Komori A, Migita K, Ito M, Nagaoka S, Abiru S, Yatsuhashi H, Yasunami M, Shimoda S, Harada K, Egawa H, Maehara Y, Uemoto S, Kokudo N, Takikawa H, Ishibashi H, Chayama K, Mizokami M, Nagasaki M, Tokunaga K, Nakamura M.

Hum Mol Genet. 2017 Feb 1;26(3):650-659. doi: 10.1093/hmg/ddw406.

PMID:
28062665
19.

KLHL3 Knockout Mice Reveal the Physiological Role of KLHL3 and the Pathophysiology of Pseudohypoaldosteronism Type II Caused by Mutant KLHL3.

Sasaki E, Susa K, Mori T, Isobe K, Araki Y, Inoue Y, Yoshizaki Y, Ando F, Mori Y, Mandai S, Zeniya M, Takahashi D, Nomura N, Rai T, Uchida S, Sohara E.

Mol Cell Biol. 2017 Mar 17;37(7). pii: e00508-16. doi: 10.1128/MCB.00508-16. Print 2017 Apr 1.

20.

Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016.

Tanaka A, Ma X, Yokosuka O, Weltman M, You H, Amarapurkar DN, Kim YJ, Abbas Z, Payawal DA, Chang ML, Efe C, Ozaslan E, Abe M, Mitchell-Thain R, Zeniya M, Han KH, Vierling JM, Takikawa H.

Hepatol Int. 2016 Nov;10(6):909-915. Epub 2016 Sep 20. Review.

PMID:
27649967
21.

Autoimmune hepatitis in Japan: trends in a nationwide survey.

Takahashi A, Arinaga-Hino T, Ohira H, Torimura T, Zeniya M, Abe M, Yoshizawa K, Takaki A, Suzuki Y, Kang JH, Nakamoto N, Fujisawa T, Yonemoto K, Tanaka A, Takikawa H; Autoimmune Hepatitis Study Group-Subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan.

J Gastroenterol. 2017 May;52(5):631-640. doi: 10.1007/s00535-016-1267-0. Epub 2016 Oct 8.

PMID:
27722997
22.

A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients.

Assis DN, Takahashi H, Leng L, Zeniya M, Boyer JL, Bucala R.

Dig Dis Sci. 2016 Dec;61(12):3506-3512. Epub 2016 Oct 1.

23.

Erratum to: Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.

Toyoda H, Kumada T, Tada T, Takaguchi K, Ishikawa T, Tsuji K, Zeniya M, Iio E, Tanaka Y.

J Gastroenterol. 2016 Jul;51(7):750. No abstract available.

PMID:
26948482
24.

Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.

Toyoda H, Kumada T, Tada T, Takaguchi K, Ishikawa T, Tsuji K, Zeniya M, Iio E, Tanaka Y.

J Gastroenterol. 2016 Jul;51(7):741-7. doi: 10.1007/s00535-016-1174-4. Epub 2016 Feb 12. Erratum in: J Gastroenterol. 2016 Jul;51(7):750.

PMID:
26872889
25.

[Kelch-like protein 2 mediates angiotensin II--With no lysine 3 signaling in the regulation of vascular tonus].

Zeniya M.

Nihon Jinzo Gakkai Shi. 2015;57(8):1323-6. Japanese. No abstract available.

PMID:
26817160
26.

Impaired degradation of WNK by Akt and PKA phosphorylation of KLHL3.

Yoshizaki Y, Mori Y, Tsuzaki Y, Mori T, Nomura N, Wakabayashi M, Takahashi D, Zeniya M, Kikuchi E, Araki Y, Ando F, Isobe K, Nishida H, Ohta A, Susa K, Inoue Y, Chiga M, Rai T, Sasaki S, Uchida S, Sohara E.

Biochem Biophys Res Commun. 2015 Nov 13;467(2):229-34. doi: 10.1016/j.bbrc.2015.09.184. Epub 2015 Oct 3.

PMID:
26435498
27.

Involvement of selective autophagy mediated by p62/SQSTM1 in KLHL3-dependent WNK4 degradation.

Mori Y, Mori T, Wakabayashi M, Yoshizaki Y, Zeniya M, Sohara E, Rai T, Uchida S.

Biochem J. 2015 Nov 15;472(1):33-41. doi: 10.1042/BJ20150500. Epub 2015 Sep 8.

PMID:
26349538
28.

Analysis of the Japanese Diabetes Risk Score and fatty liver markers for incident diabetes in a Japanese cohort.

Katoh S, Peltonen M, Zeniya M, Kaji M, Sakamoto Y, Utsunomiya K, Tuomilehto J.

Prim Care Diabetes. 2016 Feb;10(1):19-26. doi: 10.1016/j.pcd.2015.07.006. Epub 2015 Aug 21.

PMID:
26303223
29.

Autoimmune hepatitis: Diagnosis and treatment guide in Japan, 2013.

Onji M, Zeniya M, Yamamoto K, Tsubouchi H.

Hepatol Res. 2014 Apr;44(4):368-70. doi: 10.1111/hepr.12300. No abstract available.

PMID:
25989393
30.

[Hepatitis C virus infection and hemodialysis: update 2014].

Zeniya M.

Nihon Rinsho. 2015 Feb;73(2):304-11. Japanese.

PMID:
25764687
31.

Background of the FIB-4 index in Japanese non-alcoholic fatty liver disease.

Wada T, Zeniya M.

Intern Med. 2015;54(2):127-32. doi: 10.2169/internalmedicine.54.2685. Epub 2015 Jan 15.

32.

Kelch-Like Protein 2 Mediates Angiotensin II-With No Lysine 3 Signaling in the Regulation of Vascular Tonus.

Zeniya M, Morimoto N, Takahashi D, Mori Y, Mori T, Ando F, Araki Y, Yoshizaki Y, Inoue Y, Isobe K, Nomura N, Oi K, Nishida H, Sasaki S, Sohara E, Rai T, Uchida S.

J Am Soc Nephrol. 2015 Sep;26(9):2129-38. doi: 10.1681/ASN.2014070639. Epub 2015 Jan 2.

33.

Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride Transporters.

Kikuchi E, Mori T, Zeniya M, Isobe K, Ishigami-Yuasa M, Fujii S, Kagechika H, Ishihara T, Mizushima T, Sasaki S, Sohara E, Rai T, Uchida S.

J Am Soc Nephrol. 2015 Jul;26(7):1525-36. doi: 10.1681/ASN.2014060560. Epub 2014 Nov 5.

34.

Immunosuppressive therapy for primary biliary cirrhosis: Do we need in future?

Zeniya M, Wada T.

Hepatol Res. 2014 Sep;44(9):935-6. doi: 10.1111/hepr.12245. No abstract available.

PMID:
25224130
35.

Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis.

Nakamura M, Kondo H, Tanaka A, Komori A, Ito M, Yamamoto K, Ohira H, Zeniya M, Hashimoto E, Honda M, Kaneko S, Ueno Y, Kikuchi K, Shimoda S, Harada K, Arai K, Miyake Y, Abe M, Taniai M, Saibara T, Sakisaka S, Takikawa H, Onji M, Tsubouchi H, Nakanuma Y, Ishibashi H.

Hepatol Res. 2015 Aug;45(8):846-55. doi: 10.1111/hepr.12423. Epub 2014 Dec 11.

PMID:
25220608
36.

The therapeutic effect of UDCA is a factor in determining the prognosis of primary biliary cirrhosis.

Zeniya M, Wada T.

J Gastroenterol. 2014 Oct;49(10):1438-9. doi: 10.1007/s00535-014-0969-4. Epub 2014 Jun 5. No abstract available.

PMID:
24898105
37.

Impaired degradation of WNK1 and WNK4 kinases causes PHAII in mutant KLHL3 knock-in mice.

Susa K, Sohara E, Rai T, Zeniya M, Mori Y, Mori T, Chiga M, Nomura N, Nishida H, Takahashi D, Isobe K, Inoue Y, Takeishi K, Takeda N, Sasaki S, Uchida S.

Hum Mol Genet. 2014 Oct 1;23(19):5052-60. doi: 10.1093/hmg/ddu217. Epub 2014 May 12.

PMID:
24821705
38.

WNK4 is the major WNK positively regulating NCC in the mouse kidney.

Takahashi D, Mori T, Nomura N, Khan MZ, Araki Y, Zeniya M, Sohara E, Rai T, Sasaki S, Uchida S.

Biosci Rep. 2014 May 9;34(3). pii: e00107. doi: 10.1042/BSR20140047.

39.

Fatty liver and serum cholinesterase are independently correlated with HbA1c levels: cross-sectional analysis of 5384 people.

Katoh S, Peltonen M, Wada T, Zeniya M, Sakamoto Y, Utsunomiya K, Tuomilehto J.

J Int Med Res. 2014 Apr;42(2):542-53. doi: 10.1177/0300060513517485. Epub 2014 Mar 4.

PMID:
24595150
40.

Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1 autoimmune hepatitis.

Miyake Y, Yamamoto K, Matsushita H, Abe M, Takahashi A, Umemura T, Tanaka A, Nakamuta M, Nakamoto Y, Ueno Y, Saibara T, Takikawa H, Yoshizawa K, Ohira H, Zeniya M, Onji M, Tsubouchi H; Intractable Hepato-Biliary Disease Study Group of Japan.

Hepatol Res. 2014 Dec;44(13):1299-307. doi: 10.1111/hepr.12305. Epub 2014 Mar 6.

PMID:
24506172
41.

Dietary salt intake regulates WNK3-SPAK-NKCC1 phosphorylation cascade in mouse aorta through angiotensin II.

Zeniya M, Sohara E, Kita S, Iwamoto T, Susa K, Mori T, Oi K, Chiga M, Takahashi D, Yang SS, Lin SH, Rai T, Sasaki S, Uchida S.

Hypertension. 2013 Nov;62(5):872-8. doi: 10.1161/HYPERTENSIONAHA.113.01543. Epub 2013 Sep 9.

PMID:
24019400
42.

Usefulness of combined application of double-filtration plasmapheresis and twice-daily injections of interferon-β in hemodialysis patients with hepatitis C virus genotype 1b infection and a high viral load.

Zeniya M, Nakano M, Saeki C, Yokoyama K, Ishikawa T, Takaguchi K, Takahashi H.

Hepatol Res. 2014 Oct;44(10):E257-60. doi: 10.1111/hepr.12207. Epub 2013 Sep 17.

PMID:
23855529
43.

KLHL2 interacts with and ubiquitinates WNK kinases.

Takahashi D, Mori T, Wakabayashi M, Mori Y, Susa K, Zeniya M, Sohara E, Rai T, Sasaki S, Uchida S.

Biochem Biophys Res Commun. 2013 Aug 2;437(3):457-62. doi: 10.1016/j.bbrc.2013.06.104. Epub 2013 Jul 6.

PMID:
23838290
44.

[Case report: a case of polyarteritis nodosa with small intestinal perforation and renal aneurysm rupture].

Hayakawa A, Nakajima T, Satoh K, Yamazaki J, Zeniya M, Nasu K, Seyama Y, Okura Y, Tanizawa T, Inoshita S.

Nihon Naika Gakkai Zasshi. 2013 Mar 10;102(3):714-6. Japanese. No abstract available.

PMID:
23777164
45.

Application and validation of a new histologic staging and grading system for primary biliary cirrhosis.

Harada K, Hsu M, Ikeda H, Zeniya M, Nakanuma Y.

J Clin Gastroenterol. 2013 Feb;47(2):174-81. doi: 10.1097/MCG.0b013e31827234e4.

PMID:
23269312
46.

Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers.

Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, Wauthier E, Tajiri H, Miller LD, Wang XW, Reid LM, Nakauchi H.

Hepatology. 2013 Apr;57(4):1469-83. doi: 10.1002/hep.26159. Epub 2013 Mar 6.

47.

Activated natural killer T cells producing interferon-gamma elicit promoting activity to murine dendritic cell-based autoimmune hepatic inflammation.

Nakano M, Saeki C, Takahashi H, Homma S, Tajiri H, Zeniya M.

Clin Exp Immunol. 2012 Dec;170(3):274-82. doi: 10.1111/j.1365-2249.2012.04664.x.

48.

Prognosis of autoimmune hepatitis showing acute presentation.

Yamamoto K, Miyake Y, Ohira H, Suzuki Y, Zeniya M, Onji M, Tsubouchi H; Intractable Liver and Biliary Diseases Study Group of Japan.

Hepatol Res. 2013 Jun;43(6):630-8. doi: 10.1111/j.1872-034X.2012.01109.x. Epub 2012 Oct 22.

PMID:
23088515
49.

Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population.

Nakamura M, Nishida N, Kawashima M, Aiba Y, Tanaka A, Yasunami M, Nakamura H, Komori A, Nakamuta M, Zeniya M, Hashimoto E, Ohira H, Yamamoto K, Onji M, Kaneko S, Honda M, Yamagiwa S, Nakao K, Ichida T, Takikawa H, Seike M, Umemura T, Ueno Y, Sakisaka S, Kikuchi K, Ebinuma H, Yamashiki N, Tamura S, Sugawara Y, Mori A, Yagi S, Shirabe K, Taketomi A, Arai K, Monoe K, Ichikawa T, Taniai M, Miyake Y, Kumagi T, Abe M, Yoshizawa K, Joshita S, Shimoda S, Honda K, Takahashi H, Hirano K, Takeyama Y, Harada K, Migita K, Ito M, Yatsuhashi H, Fukushima N, Ota H, Komatsu T, Saoshiro T, Ishida J, Kouno H, Kouno H, Yagura M, Kobayashi M, Muro T, Masaki N, Hirata K, Watanabe Y, Nakamura Y, Shimada M, Hirashima N, Komeda T, Sugi K, Koga M, Ario K, Takesaki E, Maehara Y, Uemoto S, Kokudo N, Tsubouchi H, Mizokami M, Nakanuma Y, Tokunaga K, Ishibashi H.

Am J Hum Genet. 2012 Oct 5;91(4):721-8. doi: 10.1016/j.ajhg.2012.08.010. Epub 2012 Sep 20.

50.

Efficacy of MK615 for the treatment of patients with liver disorders.

Hokari A, Ishikawa T, Tajiri H, Matsuda T, Ishii O, Matsumoto N, Okuse C, Takahashi H, Kurihara T, Kawahara K, Maruyama I, Zeniya M.

World J Gastroenterol. 2012 Aug 21;18(31):4118-26. doi: 10.3748/wjg.v18.i31.4118.

Supplemental Content

Loading ...
Support Center